Jin10 data reported on May 13 that Jinhe Biology stated on the interactive platform that if the China-U.S. tariffs decrease, the company’s veterinary pharmaceutical export business will benefit directly. Currently, the company has effectively covered the increased tariff costs by raising the prices in the end market.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Jinhe Biology: If the US-China tariffs decrease, the company's veterinary pharmaceutical export business will directly benefit.
Jin10 data reported on May 13 that Jinhe Biology stated on the interactive platform that if the China-U.S. tariffs decrease, the company’s veterinary pharmaceutical export business will benefit directly. Currently, the company has effectively covered the increased tariff costs by raising the prices in the end market.